RayKnowChina Research Map
Shortlist

Jiaxing

Affiliated Hospital of Jiaxing University

Listed for 2 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Affiliated Hospital of Jiaxing University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Lung cancer肺癌32 papers led
  2. Pancreatic cancer胰腺癌9 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Lung cancer

肺癌

Led 32 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
32
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 6620212022: 8820222023: 5520232024: 5520242025: 772025

1 hospital in Jiaxing for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic Surgery
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07849400

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Jiaxing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led32
  1. Circ_0105487 Promotes the Metastasis of Triple-Negative Breast Cancer via Epithelial-Mesenchymal Transition.2026Biotechnology and applied biochemistry
  2. Progress in Development of Lung Cancer Survival Prediction Models Using Machine Learning Based on SEER Database.2025Cancer investigation
  3. Longitudinal single-cell RNA model aids prediction of EGFR-TKI resistance.2025Carcinogenesis
  4. ERCC6L-mediated stabilization of HIF-1α enhances glycolysis and stemness properties of lung adenocarcinoma cells.2025Cell death & diseaseFree full text
  5. TCF3 activates VEGFA transcription and reinforces PD-L1 expression in lung adenocarcinoma cells via NF-κB to attenuate the cytotoxicity of CD8+ T cells.2025Expert review of clinical immunology
  6. Akkermansia muciniphila-derived outer membrane protein Amuc_1100 promotes acetylation of RING Finger Protein 181 promoter and mediates Autophagy Related 7 ubiquitination to activate CD8+ T cells in lung adenocarcinoma.2025International journal of biological macromolecules
  7. Clinicopathologic features and therapeutic outcomes in EGFR/ALK-aberrations NSCLC with histologic transformation.2025Journal of translational medicineFree full text
  8. Network pharmacological mechanism and molecular experimental validation of artemisinin in the treatment of lung adenocarcinoma.2025Toxicology and applied pharmacology
  9. MiR-301b-3p can be used as a Potential Marker for the Diagnosis of Lung Adenocarcinoma.2024Combinatorial chemistry & high throughput screening
  10. LncRNA HCG11 enhances the chemosensitivity of non-small cell lung cancer cells to Gemcitabine via miR-17-5p/p21 axis.2024Expert review of anticancer therapy
  11. CT-based intratumoral and peritumoral deep transfer learning features prediction of lymph node metastasis in non-small cell lung cancer.2024Journal of X-ray science and technology
  12. Liquid Biopsy in Lung Cancer: Nano-Flow Cytometry Detection of Non-Small Cell Lung Cancer in Blood.2024Laboratory investigation; a journal of technical methods and pathology
  13. Akkermansia muciniphila outer membrane protein regulates recruitment of CD8+ T cells in lung adenocarcinoma and through JAK-STAT signalling pathway.2024Microbial biotechnologyFree full text
  14. EIF4A3-induced circular RNA SCAP facilitates tumorigenesis and progression of non-small-cell lung cancer via miR-7/SMAD2 signaling.2023Environmental science and pollution research internationalFree full text
  15. Preparation, characterisation, and in vitro cancer-suppression function of RNA nanoparticles carrying miR-301b-3p Inhibitor.2023IET nanobiotechnologyFree full text
  16. Investigation of the Potential Correlation Between RNA-Binding Proteins in the Evolutionarily Conserved MEX3 Family and Non-small-Cell Lung Cancer.2023Molecular biotechnologyFree full text
  17. TFAP2A activates HMGA1 to promote glycolysis and lung adenocarcinoma progression.2023Pathology, research and practice
  18. Sublobar resection versus lobectomy in the treatment of synchronous multiple primary lung cancer.2023World journal of surgical oncologyFree full text
  19. Development and validation of a prognostic nomogram for early stage non-small cell lung cancer: a study based on the SEER database and a Chinese cohort.2022BMC cancerFree full text
  20. A Clinical Study on Microwave Ablation in Combination with Chemotherapy in Treating Peripheral IIIB-IV Non-Small Cell Lung Cancer.2022Cancer biotherapy & radiopharmaceuticalsRCT
  21. MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis.2022Cellular signalling
  22. TRIM66 Promotes Malignant Progression of Non-Small-Cell Lung Cancer Cells via Targeting MMP9.2022Computational and mathematical methods in medicineFree full text
  23. TRIM66 hastens the malignant progression of non-small cell lung cancer via modulating MMP9-mediated TGF-β/SMAD pathway.2022Cytokine
  24. Prognostic value of metabolic genes in lung adenocarcinoma via integrative analyses.2022Genomics
  25. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.2022Medical oncology (Northwood, London, England)
  26. The combination of decitabine and aspirin inhibits tumor growth and metastasis in non-small cell lung cancer.2022The Journal of international medical researchFree full text
  27. MiR-133b suppresses the proliferation, migration and invasion of lung adenocarcinoma cells by targeting SKA3.2021Cancer biology & therapyFree full text
  28. Value of Growth/Differentiation Factor 15 in Diagnosis and the Evaluation of Chemotherapeutic Response in Lung Cancer.2021Clinical therapeutics
  29. DLC1 inhibits lung adenocarcinoma cell proliferation, migration and invasion via regulating MAPK signaling pathway.2021Experimental lung research
  30. New biomarker for lung cancer - focus on circSETD3.2021Journal of biological regulators and homeostatic agents
  31. Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy.2021Journal of cancer research and clinical oncologyFree full text
  32. MIR-301b-3p Promotes Lung Adenocarcinoma Cell Proliferation, Migration and Invasion by Targeting DLC1.2021Technology in cancer research & treatmentFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for Thoracoscopic SurgeryNot yet recruitingNCT07849400Study siteN/AStart 2026-10

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 9 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 3320242025: 222025

2 hospitals in Jiaxing for pancreatic cancer192 hospitals in China for pancreatic cancer

No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led9
  1. Metabolomics to Reveal Diagnostic Biomarkers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma: A Cross-Sectional Study.2026Journal of proteome research
  2. Single-cell and multi-omics analysis identifies TRIM9 as a key ubiquitination regulator in pancreatic cancer.2025Frontiers in immunologyFree full text
  3. Impact of microvasculature invasion subtype (MVI vs. LVI) and associated risk factors on survival outcomes in pancreatic cancer after curative surgery.2025World journal of surgical oncologyFree full text
  4. Nomogram incorporating prognostic immune-inflammatory-nutritional score for survival prediction in pancreatic cancer: a retrospective study.2024BMC cancerFree full text
  5. Construction of a combined prognostic model for pancreatic ductal adenocarcinoma based on deep learning and digital pathology images.2024BMC gastroenterologyFree full text
  6. miR-630 as a therapeutic target in pancreatic cancer stem cells: modulation of the PRKCI-Hedgehog signaling axis.2024Biology directFree full text
  7. A necroptosis related prognostic model of pancreatic cancer based on single cell sequencing analysis and transcriptome analysis.2022Frontiers in immunologyFree full text
  8. Low Serum miR-607 Level as a Potential Diagnostic and Prognostic Biomarker in Patients of Pancreatic Ductal Adenocarcinoma: A Preliminary Study.2021Canadian journal of gastroenterology & hepatologyFree full text
  9. LINC00261 elevation inhibits angiogenesis and cell cycle progression of pancreatic cancer cells by upregulating SCP2 via targeting FOXP3.2021Journal of cellular and molecular medicineFree full text

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

Affiliated Hospital of Jiaxing University

嘉兴

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data